NASD · Healthcare · Biotechnology · USA
PTC Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
PTC Therapeutics is a global biopharmaceutical company that discovers, develops and commercializes medicines for rare disorders in children and adults. The company markets several approved products including Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza/Kebilidi for AADC deficiency, and Evrysdi for spinal muscular atrophy.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the PTC Therapeutics Inc stock.
Undervalued: intrinsic value $162.03 per share, market price $61.53, margin of safety 62.0% (as of 2026-10-19).
Discounting its cash flows at 8.1% (average of 2 methods) values the shares at $162.03; the price of $61.53 is 62% below that value, and 81% of that value comes from beyond year five.
Leak Score: 70/100 on 9 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
2 more in this industry show a wider margin of safety.
PTCT is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 8.1% (average of 2 methods) values the shares at $162.03; the price of $61.53 is 62% below that value, and 81% of that value comes from beyond year five.
$162.03 per share (as of the 2026-10-19 close), against a market price of $61.53. That is a margin of safety of 62.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
70 out of 100, which we rate "Clear Leak", on 9 of 12 value investing signals.